METOPROLOL SUCCINATE

Post-LOE

metoprolol succinate

Cipla

ANDAORALTABLET, EXTENDED RELEASE

Approved

Oct 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

2/8 — Basic

Drug data last refreshed 3d ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (9)

NCT05767346Phase 3Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Started Jun 2023

175 enrolled

Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT01508325Phase 4Completed

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients

Started Dec 2011

186 enrolled

Hypertension

NCT01694797Phase 1Completed

Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition

Started Jan 2011

48 enrolled

Healthy

NCT01673997Phase 1Completed

Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions

Started Dec 2010

48 enrolled

Healthy

NCT01248338Phase 4Completed

Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function

Started Mar 2006

80 enrolled

Hypertension

Worked on METOPROLOL SUCCINATE at Cipla? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.